Kobayashi M, Sugaya Y, Yuzawa M, Ochi M, Morita T, Kobayashi Y, Tokue A, Hara Y
Dept. of Urology, Jichi Medical School.
Gan To Kagaku Ryoho. 1998 Sep;25(11):1771-4.
The present study was designed to investigate the appropriate intravesical retention time of pirarubicin (THP) for the treatment of bladder tumor in terms of its anti-tumor effect and side effect. We administered THP to 22 patients with superficial bladder tumor intravesically and measured the THP concentration in the tumor tissues. Patients were divided into 3 groups by retention time; 8 for 30 minutes, 8 for 1 hour and 7 for 2 hours. Tumor tissues were obtained by transurethral resection 30 min., 1 or 2 hours after the intravesical instillation of THP at the fixed concentrations of 30 mg/30 ml. There was no significant difference in THP concentration between 3 groups. This indicates that the anti-tumor effect of intravesical instillation of the THP would be expected by only 30 min. of intravesical retention time at the THP concentration of 30 mg/30 ml. Then, we administered 30 mg/30 ml of THP solution for 30 min. to 10 patients intravesically 6 times every 48 hours to investigate its clinical anti-tumor effect and side effect. There were 2 complete responses, 3 partial responses and 5 cases with no changes for a total response rate of 50%. No side effect was observed. It is considered that 30 min. of intravesical retention time at the THP concentration of 30 mg/30 ml would be appropriate in terms of its anti-tumor effect and side effect.
本研究旨在从吡柔比星（THP）的抗肿瘤效果和副作用方面，探讨其治疗膀胱肿瘤时合适的膀胱内保留时间。我们对22例浅表性膀胱肿瘤患者进行膀胱内灌注THP，并测量肿瘤组织中的THP浓度。根据保留时间将患者分为3组；8例保留30分钟，8例保留1小时，7例保留2小时。在固定浓度为30mg/30ml的THP膀胱内灌注30分钟、1小时或2小时后，通过经尿道切除术获取肿瘤组织。3组之间的THP浓度无显著差异。这表明在THP浓度为30mg/30ml时，仅30分钟的膀胱内保留时间即可预期膀胱内灌注THP的抗肿瘤效果。然后，我们对10例患者每48小时进行6次膀胱内灌注30mg/30ml的THP溶液30分钟，以研究其临床抗肿瘤效果和副作用。有2例完全缓解，3例部分缓解，5例无变化，总缓解率为50%。未观察到副作用。从抗肿瘤效果和副作用方面考虑，在THP浓度为30mg/30ml时30分钟的膀胱内保留时间是合适的。
